110 related articles for article (PubMed ID: 25775444)
1. Catastrophic eruptive keratoacanthomas and squamous cell cancers after treatment with an FLT3 inhibitor quizartinib (AC220).
Altman K; Sharata H
Dermatol Surg; 2015 Apr; 41(4):530-1. PubMed ID: 25775444
[No Abstract] [Full Text] [Related]
2. The role of quizartinib in the treatment of acute myeloid leukemia.
Ostronoff F; Estey E
Expert Opin Investig Drugs; 2013 Dec; 22(12):1659-69. PubMed ID: 24070241
[TBL] [Abstract][Full Text] [Related]
3. Quizartinib for the treatment of acute myeloid leukemia.
Garcia-Horton A; Yee KW
Expert Opin Pharmacother; 2020 Dec; 21(17):2077-2090. PubMed ID: 32772726
[TBL] [Abstract][Full Text] [Related]
4. Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia.
Levis M
Future Oncol; 2014; 10(9):1571-9. PubMed ID: 25145428
[TBL] [Abstract][Full Text] [Related]
5. Quizartinib in acute myeloid leukemia.
Levis M
Clin Adv Hematol Oncol; 2013; 11(9):586-8. PubMed ID: 24518522
[No Abstract] [Full Text] [Related]
6. Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib.
Taylor SJ; Duyvestyn JM; Dagger SA; Dishington EJ; Rinaldi CA; Dovey OM; Vassiliou GS; Grove CS; Langdon WY
Sci Transl Med; 2017 Aug; 9(402):. PubMed ID: 28794285
[TBL] [Abstract][Full Text] [Related]
7. Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia.
Fathi AT; Lin WM; Durazzo T; Piris A; Sadrzadeh H; Bernardo L; Borger DR; McAfee SL; Kroshinsky D; Chen YB
J Clin Oncol; 2016 Mar; 34(8):e70-2. PubMed ID: 25024084
[No Abstract] [Full Text] [Related]
8. Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study.
Usuki K; Handa H; Choi I; Yamauchi T; Iida H; Hata T; Ohwada S; Okudaira N; Nakamura K; Sakajiri S
Int J Hematol; 2019 Dec; 110(6):654-664. PubMed ID: 31359361
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.
Papadopoulos KP; Ben-Ami E; Patnaik A; Trone D; Li J; Demetri GD
BMC Cancer; 2018 Aug; 18(1):790. PubMed ID: 30081867
[TBL] [Abstract][Full Text] [Related]
10. A critical appraisal of Japan's new drug approval process: a case study of FLT3-ITD inhibitor quizartinib.
Kidoguch K; Shibusawa M; Tanimoto T
Invest New Drugs; 2021 Dec; 39(6):1457-1459. PubMed ID: 34268710
[TBL] [Abstract][Full Text] [Related]
11. Safety and Pharmacokinetics of Quizartinib Combination Therapy With Standard Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results from Two Phase 1 Trials in Japan and China.
Qi J; Choi I; Ota S; Ichikawa S; Fujishima N; Iida H; Sugiura I; Sugiura K; Murata Y; Inoue H; Ohwada S; Wang J
Clin Pharmacol Drug Dev; 2024 May; 13(5):560-571. PubMed ID: 38284515
[TBL] [Abstract][Full Text] [Related]
12. The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220.
Pauwels D; Sweron B; Cools J
Haematologica; 2012 Nov; 97(11):1773-4. PubMed ID: 22875611
[No Abstract] [Full Text] [Related]
13. Notch blockade overcomes endothelial cell-mediated resistance of FLT3/ITD-positive AML progenitors to AC220 treatment.
Le Q; Hadland B; Meshinchi S; Bernstein I
Leukemia; 2021 Feb; 35(2):601-605. PubMed ID: 32513964
[No Abstract] [Full Text] [Related]
14. Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone.
Nybakken GE; Canaani J; Roy D; Morrissette JD; Watt CD; Shah NP; Smith CC; Bagg A; Carroll M; Perl AE
Leukemia; 2016 Jun; 30(6):1422-5. PubMed ID: 26585411
[No Abstract] [Full Text] [Related]
15. Effect of Food on the Pharmacokinetics of Quizartinib.
Li J; Holmes M; Kankam M; Trone D; Mendell J; Gammon G
Clin Pharmacol Drug Dev; 2020 Feb; 9(2):277-286. PubMed ID: 31916418
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220).
Zorn JA; Wang Q; Fujimura E; Barros T; Kuriyan J
PLoS One; 2015; 10(4):e0121177. PubMed ID: 25837374
[TBL] [Abstract][Full Text] [Related]
17. The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia.
Smith CC; Shah NP
Am Soc Clin Oncol Educ Book; 2013; ():313-8. PubMed ID: 23714533
[TBL] [Abstract][Full Text] [Related]
18. Quizartinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: More Patients Make It to Transplant, but Are There Any Other Benefits?
Hunter BD
Transplant Cell Ther; 2021 Feb; 27(2):99-100. PubMed ID: 33781547
[No Abstract] [Full Text] [Related]
19. A drug-drug interaction study to assess the potential effect of acid-reducing agent, lansoprazole, on quizartinib pharmacokinetics.
Li J; Trone D; Mendell J; O'Donnell P; Cook N
Cancer Chemother Pharmacol; 2019 Oct; 84(4):799-807. PubMed ID: 31385001
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib monotherapy gives sustainable suppression of FLT3 clone in untreated patients with FLT3-internal tandem duplication positive acute myeloid Leukaemia.
Mohan BP; How GF; Loh Y; Linn YC
Br J Haematol; 2012 Apr; 157(1):131-2. PubMed ID: 22050655
[No Abstract] [Full Text] [Related]
[Next] [New Search]
